TuHURA Biosciences, Inc. HURA
1.25 USD -0.11 (-8.09%)
Regular-session close
1.26 +0.01 +0.80%
After hours · Nov 20, 6:12 PM ET
1.24 Day range 1.41
0.44 52-week range 3.15
- YTD
- +65.13%
- 1 year
- -21.38%
5D -0.11 (-8.09%)
- Market cap
- 82.20M
- EPS (ttm)
- -0.50
- Forward P/E
- -14.31
- YTD return
- +65.13%
- 1-year return
- -21.38%
- 50-day average
- 5.22
- 200-day average
- 6.16
- Volume
- 523.92K
- Avg volume
- 327.59K
- Open
- 1.34
- Previous close
- 1.36
- Day's range
- 1.24 – 1.41
- 52-week range
- 0.44 – 3.15
- Price target
- 15.00 (+1100.0%)
Fundamental scorecard
1 of 25 checks passed on HURA’s reported financials
1of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 0 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
HURA Revenue — quarterly 0
HURA Net income — quarterly -6.41M
HURA EPS — quarterly -0.10
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 12, 2025 | Dec 1, 2024 | 0.00 | — | — | — |
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -1.37 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | Rodman & Renshaw | init | — | Buy |
News
HC Wainwright & Co. Reiterates Buy on TuHURA Biosciences, Maintains $10 Price Target
TuHURA Biosciences Q3 EPS $(0.10) Beats $(0.14) Estimate
HC Wainwright & Co. Reiterates Buy on TuHURA Biosciences, Maintains $10 Price Target
TuHURA Reports Initial Data Showing Partial Responses In First Three Metastatic Merkel Cell Carcinoma Patients Treated With Ifx-2.0 Plus Keytruda
Your note
Sign in to keep a note on HURA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BIANCO JAMES A | Chief Executive Officer | Stock Award(Grant) | Oct 17, 2024 | 2,323,310 |
| HOFFMAN ROBERT E | Chief Executive Officer | Stock Award(Grant) | May 31, 2023 | 68,902 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.06% | 25,394 | 105.39K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.02% | 7,297 | 30.28K | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 0.01% | 4,558 | 18.91K | Sep 29, 2024 |
| UBS Group AG | 0.01% | 5,930 | 24.61K | Sep 29, 2024 |
| Clear Creek Financial Management, LLC | 0.00% | 1,571 | 6.52K | Sep 29, 2024 |
| Baader Bank Aktiengesellschaft | 0.00% | 864 | 3.58K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.02% | 8,960 | 37.18K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.01% | 2,489 | 10.33K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.00% | 712 | 2.95K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.00% | 1,546 | 6.42K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.00% | 870 | 3.61K | Oct 30, 2024 |
